Feasibility of site- directed delivery of endolysins for targeted antibacterial therapy

内溶素定点递送用于靶向抗菌治疗的可行性

• 批准号: 131622
• 金额: $ 14.65万
• 依托单位: CAMBIMUNE LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131622
• 关键词: Feasibility; site; directed; delivery; endolysins

In light of rapidly emerging bacterial resistance to antibiotics, novel antimicrobials that are more refractory to resistance development are urgently needed. This project will test the feasibility of using targeted delivery of potent and highly specific novel antibiotic compounds. We will evaluate the feasibility of our approach in the context of Clostridium difficile (C.diff). C.diff infections (CDI) are the most frequent hospital-acquired infections in many industrialised countries driven by the emergence of highly virulent, antibiotic -resistant, strains.The disease results when the normal gut flora is disturbed, primarily as a consequence of broad-spectrum antibiotic use, leading to an overgrowth of C. diff. There is a pressing need for a therapeutic regimen that will suppress or remove C.diff without damaging or disrupting the normal bacterial flora of the gut.

鉴于细菌对抗生素的耐药性迅速出现，迫切需要更不易产生耐药性的新型抗菌素。该项目将测试使用靶向递送强效和高度特异性的新型抗生素化合物的可行性。我们将在艰难梭菌（C.diff）的背景下评估我们的方法的可行性。艰难梭菌感染（CDI）是许多工业化国家最常见的医院获得性感染，是由高毒力、抗生素耐药菌株的出现引起的。当正常的肠道菌群受到干扰时，主要是由于广谱抗生素的使用，导致艰难梭菌的过度生长。迫切需要一种治疗方案，既能抑制或去除艰难梭菌，又不会损害或破坏肠道正常的细菌菌群。